> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# US Bioservices Corp. Settles Fraud Suit for $13.4 Million
- URL: https://www.fdaweb.com/us-bioservices-corp-settles-fraud-suit-for-13-4-million/
- Published: 2017-08-24T12:00:00.000Z
- Updated: 2026-09-14T22:43:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139462

US Bioservices Corp. will pay $13.4 million to settle claims that the company violated the anti-kickback law and the False Claims Act by participating in a kickback scheme with Novartis involving its iron-lowering drug Exjade (desfirasirox). According to a Justice Department [news release](https://www.justice.gov/usao-sdny/pr/acting-manhattan-us-attorney-announces-134-million-settlement-civil-healthcare-fraud?ref=fdaweb.com), US Bioservices was promised additional patient referrals by Novartis and related benefits in return for refilling a higher percentage of Exjade than the two other specialty pharmacies that also dispensed it.

The company will pay about $10.6 million to the federal government and about $2.8 million to resolve numerous state law civil fraud claims.

In prior lawsuits, the government says, Novartis paid $390 million to settle claims against it and the other two pharmacies paid $75 million.